← Back to Search

Caspase-1 Inhibitor

Belnacasan for COVID-19

Phase 2
Waitlist Available
Led By Glenn Wortmann, MD
Research Sponsored by MedStar Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject (or legally authorized representative) provides written informed consent prior to the initiation of any study procedures
Subject understands and agrees to comply with planned study procedures, including using the diary
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 4, 7, 10, 14, 21, 28, 42, 60 post randomization
Awards & highlights

Study Summary

This trial will test if a drug called belnacasan is safe and effective for treating patients with mild to moderate COVID-19. If it is, it could be used in future trials.

Eligible Conditions
  • COVID-19
  • Coronavirus

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 4, 7, 10, 14, 21, 28, 42, 60 post randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 4, 7, 10, 14, 21, 28, 42, 60 post randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety and Tolerability of Belnacasan
Secondary outcome measures
Changes on the WHO 9-Point Ordinal Scale
Perinatal death
Experiences of normal surrogate markers of COVID-19-related inflammation and organ involvement
+12 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: InterventionalExperimental Treatment1 Intervention
900mg dose TID Administration Total: 2700mg
Group II: PlaceboPlacebo Group1 Intervention
900mg dose TID Administration Total: 2700mg
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Belnacasan
2021
Completed Phase 2
~50

Find a Location

Who is running the clinical trial?

MedStar HealthLead Sponsor
4 Previous Clinical Trials
70,398 Total Patients Enrolled
Glenn Wortmann, MDPrincipal InvestigatorMedStar Health
1 Previous Clinical Trials
414 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~13 spots leftby Mar 2025